Article Information
- Received September 16, 2013
- Revision received April 3, 2014
- Accepted April 21, 2014
- First published June 25, 2014.
- Version of record published June 25, 2014.
Author Information
- Markus P. Kummer1,*,
- Thea Hammerschmidt1,2,*,
- Ana Martinez3,
- Dick Terwel1,
- Gregor Eichele3,
- Anika Witten5,
- Stefanie Figura5,
- Monika Stoll5,
- Stephanie Schwartz1,
- Hans-Christian Pape2,
- Joachim L. Schultze4,
- David Weinshenker6, and
- Michael T. Heneka1,7
- 1Department of Neurology, Clinical Neurosciences Unit, University of Bonn, 53127 Bonn, Germany,
- 2Institute of Physiology I, Westfälische Wilhelms-University Münster, 48149 Münster, Germany,
- 3Genes and Behavior Department, Max Planck Institute of Biophysical Chemistry, 37077 Göttingen, Germany,
- 4LIMES Institute, Genomics and Immunoregulation, University of Bonn, 53115 Bonn, Germany,
- 5Leibniz-Institut für Arterioskleroseforschung, Genetische Epidemiologie vaskulärer Erkrankungen, 48149 Münster, Germany,
- 6Department of Human Genetics, Emory University, Atlanta, Georgia 30322, and
- 7German Center for Neurodegenerative Diseases, 53127 Bonn, Germany
Author contributions
Author contributions: M.P.K., T.H., D.T., G.E., H.-C.P., J.L.S., D.W., and M.T.H. designed research; M.P.K., T.H., A.M., A.W., S.F., and S.S. performed research; M.P.K., T.H., A.M., D.T., A.W., S.F., and M.S. analyzed data; M.P.K., T.H., D.W., and M.T.H. wrote the paper.
↵*M.P.K. and T.H. contributed equally to this work.
Disclosures
- Received September 16, 2013.
- Revision received April 3, 2014.
- Accepted April 21, 2014.
This work was supported by grants from the INMiND project and the Cluster of Excellence “ImmunoSensation” to M.T.H., the Interdisciplinary Center of Clinical Research (IZKF; HEN3/003/06) to M.T.H. and H.-C.P., the Institute for the Study of Aging to D.W., and a pilot grant from the Emory University Alzheimer's Disease Research Center (PHS AG025688) to D.W., M.T.H. is a member of the DFG Cluster of Excellence “ImmunoSensation.” We thank the Dainippon Sumitomo Pharmaceutical Company for the generous gift of l-threo DOPS. We also thank C. Jerome and C. Hülsmann for excellent technical assistance.
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Michael T. Heneka, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany. michael.heneka{at}ukb.uni-bonn.de
Online Impact
Article usage
In this issue
